Publication in Federal Register Tomorrow Moves BELVIQ® (lorcaserin HCl) Closer To Launch

Publication in Federal Register Tomorrow Moves BELVIQ® (lorcaserin HCl) Closer
                                  To Launch

PR Newswire

WOODCLIFF LAKE, N.J., May 7, 2013

WOODCLIFF LAKE, N.J., May 7, 2013 /PRNewswire/ --Eisai Inc. announced today
that the U.S. Drug Enforcement Administration (DEA) has placed BELVIQ
(pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. This
information is expected to be published in the Federal Register on May 8, with
an effective date of June 7, 2013. Eisai will issue a public statement when
BELVIQ is available in the U.S.

BELVIQ was approved by the FDA on June 27, 2012 for chronic weight management
in adults who are overweight with a comorbidity or obese.

About BELVIQ (lorcaserin HCl) Tablets

BELVIQ is believed to decrease food consumption and promote satiety by
selectively activating serotonin 2C receptors in the brain. The exact
mechanism of action of BELVIQ is not known. BELVIQ is a federally controlled
substance (CIV) because it may be abused or lead to drug dependence.

Indications

BELVIQ is used along with a reduced-calorie diet and increased physical
activity for chronic weight management in adults who have a:

  oBody mass index (BMI) of 30 kg/m^2 or greater (obese), or
  oBMI of 27 kg/m^2 or greater (overweight) with at least one weight-related
    medical condition such as high blood pressure, high cholesterol, or type 2
    diabetes.

Limitations of Use:

  oThe safety and effectiveness of BELVIQ in combination with prescription,
    over-the-counter, and herbal weight loss products is not known.
  oIt is not known if BELVIQ changes the risk of heart problems or stroke, or
    death due to heart problems or stroke.

Important Safety Information

  oPregnancy: Do not take BELVIQ if you are pregnant or planning to become
    pregnant. BELVIQ may harm your unborn baby, as weight loss offers no
    potential benefit to a pregnant woman.
  oSerotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions:
    Before using BELVIQ, tell your doctor about all the medicines you take,
    especially medicines that treat depression, migraines, mental problems, or
    the common cold. These medicines may cause serious or life-threatening
    side effects if taken with BELVIQ. Call your doctor right away if you
    experience agitation, hallucinations, confusion, or other changes in
    mental status; coordination problems; uncontrolled muscle spasms; muscle
    twitching; restlessness; racing or fast heartbeat; high or low blood
    pressure; sweating; fever; nausea; vomiting; diarrhea; or stiff muscles.
  oValvular heart disease: Some people taking medicines like BELVIQ have had
    heart valve problems. Call your doctor right away if you experience
    trouble breathing; swelling of the arms, legs, ankles, or feet; dizziness,
    fatigue, or weakness that will not go away; or fast or irregular
    heartbeat. Before taking BELVIQ, tell your doctor if you have or have had
    heart problems.
  oChanges in attention or memory: BELVIQ may slow your thinking. You should
    not drive a car or operate heavy equipment until you know how BELVIQ
    affects you.
  oMental problems: Taking too much BELVIQ may cause hallucinations, feeling
    high or in a very good mood, or feelings of standing outside of your body.
  oDepression or thoughts of suicide: Call your doctor right away if you
    notice any mental changes, especially sudden changes in your mood,
    behaviors, thoughts, or feelings, or if you have depression or thoughts of
    suicide.
  oLow blood sugar: Weight loss can cause low blood sugar in people taking
    medicines for type 2 diabetes, such as insulin or sulfonylureas. Blood
    sugar levels should be checked before and while taking BELVIQ. Changes to
    diabetes medication may be needed if low blood sugar develops.
  oPainful erections: If you have an erection lasting more than 4 hours while
    on BELVIQ, stop using BELVIQ and call your doctor or go to the nearest
    emergency room right away.
  oSlow heart beat: BELVIQ may cause your heart to beat slower.
  oDecreases in blood cell count: BELVIQ may cause your red and white blood
    cell count to decrease.
  oIncrease in prolactin: BELVIQ may increase the amount of a hormone called
    prolactin. Tell your doctor if your breasts begin to make milk or a milky
    fluid or if you are a male and your breasts begin to increase in size.
  oMost common side effects in patients without diabetes: Headache,
    dizziness, fatigue, nausea, dry mouth, and constipation.
  oMost common side effects in patients with diabetes: Low blood sugar,
    headache, back pain, cough, and fatigue.
  oNursing: BELVIQ should not be taken while breastfeeding.
  oDrug Interactions: Before taking BELVIQ, tell your doctor if you take
    medicines for depression, migraines or other medical conditions such as:
    triptans, medicines used to treat mood, anxiety, psychotic or thought
    disorders, including tricyclics, lithium, selective serotonin reuptake
    inhibitors, selective serotonin-norepinephrine reuptake inhibitors,
    monoamine oxidase inhibitors, or antipsychotics; cabergoline; linezolid
    (an antibiotic), tramadol, dextromethorphan (an over-the-counter (OTC)
    common cold/cough medicine), OTC supplements such as tryptophan or St.
    John's Wort, or erectile dysfunction medicines.

For more information about BELVIQ, click here for the full Product Information
or visit www.BELVIQ.com. 

Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., our passionate commitment to patient care is the driving force behind
our efforts to help address unmet medical needs. We are a fully integrated
pharmaceutical business with discovery, clinical, manufacturing and marketing
capabilities. Our key areas of commercial focus include oncology and specialty
care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more
about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based
programs.

BELVIQ^® is a registered trademark of Arena Pharmaceuticals GmbH.

Media Inquiries Investor Inquiries
Marcia Diljak   Alex Scott
Eisai Inc.      Eisai Inc.
(201) 746-2236  (201) 746-2177

SOURCE Eisai Inc.

Website: http://www.eisai.com